Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1). In December 2024, a ...

Video content above is prompted by the following: How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular ...

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining ...

As part of the Johns Hopkins Wilmer Eye Institute’s MACULA 2025 and the 5th Annual Retina Festival, Christina Y. Weng, MD, MBA, gave a presentation titled “Home Monitoring for Age-Related Macular ...

Over the past several decades, vision researchers have recognized that cerebral/cortical visual impairment (CVI) is a leading cause of pediatric visual impairment in the US and other industrialized ...

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to ...

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to ...